Systemic 1-methyl, 4-phenyl, 1-2-3-6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates
- 1 January 1988
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 43 (3) , 255-262
- https://doi.org/10.1016/0024-3205(88)90315-3
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- VISUAL DYSFUNCTION IN PARKINSON'S DISEASEBrain, 1987
- Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+Neuroscience Letters, 1987
- Assay of dopamine and its metabolites in human and rat retinaNeuroscience Letters, 1987
- IV. MPTP, MPP+ and mitochondrial functionLife Sciences, 1987
- Visual evoked cortical potentials and pattern electroretinograms in Parkinson's disease and control subjects.Journal of Neurology, Neurosurgery & Psychiatry, 1986
- Visual evoked potentials in parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans.Journal of Neurology, Neurosurgery & Psychiatry, 1986
- Autoradiography of l–Methyl–4–phenyl–l,2,3,6–tetrahydropyridine (MPTP): Uptake in the Monoaminergic Pathways and in Melanin Containing TissuesActa Pharmacologica et Toxicologica, 1985
- Dopaminergic neurons in the human retinaJournal of Comparative Neurology, 1982
- Simultaneous determination of catecholamines and unconjugated 3,4-dihydroxyphenylacetic acid in brain tissue by ion-pairing reverse-phase high-performance liquid chromatography with electrochemical detectionAnalytical Biochemistry, 1980
- Measurements of Visual Evoked Potentials in Parkinson's DiseaseBrain, 1978